Antagonistic CD40 monoclonal antibodies and uses in treating immune responses

US11254750B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Aaron P. YAMNIUK · Lawrenceville, US
• Mary Struthers · Edison, US
• Stanley Krystek · Ringoes, US
• Akbar Nayeem · Newtown, US
• Ginger Rakestraw · Cambridge, US

Key dates

• Filing date: Oct 26, 2020
• Grant date: Feb 22, 2022
• Expiry date: Oct 26, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.